Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Non-infectious Active Cryoglobulinemia Vasculitis (TRIBECA)
NCT04629144Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cryoglobulinemic vasculitis comparing Belimumab with Placebo (2 arms). Primary endpoint: Complete clinical response rate at week 25 with corticosteroid withdrawal at week 12. Started Oct 2021; status: recruiting.
02
Drugs
belimumab
03
Conditions
cryoglobulinemic vasculitis
Beyond the preview
Go deeper on NCT04629144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629144.